Feed GRFS
GR

Grifols GRFS · NASDAQ

$7.64 +1.33% (+$0.10)

Market cap
5.69B €
Enterprise value
13.7B €
P/E
12.6x
Forward P/E
9.7x
PEG
0.1x
P/S
0.8x
P/FCF
7.9x
EV/EBITDA
7.8x
ROIC
5.5%
Bruto marža
37.2%
Neto marža
6.1%
Dividend yield
1.25%
Payout ratio
15.7%
Neto dolg/EBITDA
4.6x
Beta
1.19
Free float
98.7%

O podjetju

Grifols, S.A. is a global Spanish pharmaceutical and biotechnology company specializing in the production of plasma-derived medicines and healthcare products. The company focuses on producing immunoglobulins, albumin, and other plasma-based products that are essential for the treatment of various diseases, including immunological and neurological disorders. Grifols also develops diagnostic tools and systems for hospitals and clinics. The company has a broad global presence and operates in over 30 countries worldwide.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jose Ignacio Abia Buenache

Employees

25,258

Headquarters

Barcelona

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.